Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK

Jia Wei, Philippa C. Matthews, Nicole Stoesser, John N. Newton, Ian Diamond, Ruth Studley, Nick Taylor, John I. Bell, Jeremy Farrar, Jaison Kolenchery, Brian D. Marsden, Sarah Hoosdally, E. Yvonne Jones, David I. Stuart, Derrick W. Crook, Tim E. A. Peto, A. Sarah Walker, Koen B. Pouwels and David W. Eyre ()
Additional contact information
Jia Wei: University of Oxford
Philippa C. Matthews: University of Oxford
Nicole Stoesser: University of Oxford
John N. Newton: University of Exeter
Ian Diamond: Office for National Statistics
Ruth Studley: Office for National Statistics
Nick Taylor: Office for National Statistics
John I. Bell: University of Oxford
Jeremy Farrar: Wellcome Trust
Jaison Kolenchery: University of Oxford
Brian D. Marsden: University of Oxford
Sarah Hoosdally: University of Oxford
E. Yvonne Jones: University of Oxford
David I. Stuart: University of Oxford
Derrick W. Crook: University of Oxford
Tim E. A. Peto: University of Oxford
A. Sarah Walker: University of Oxford
Koen B. Pouwels: The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford
David W. Eyre: University of Oxford

Nature Communications, 2023, vol. 14, issue 1, 1-15

Abstract: Abstract Following primary SARS-CoV-2 vaccination, whether boosters or breakthrough infections provide greater protection against SARS-CoV-2 infection is incompletely understood. Here we investigated SARS-CoV-2 antibody correlates of protection against new Omicron BA.4/5 (re-)infections and anti-spike IgG antibody trajectories after a third/booster vaccination or breakthrough infection following second vaccination in 154,149 adults ≥18 y from the United Kingdom general population. Higher antibody levels were associated with increased protection against Omicron BA.4/5 infection and breakthrough infections were associated with higher levels of protection at any given antibody level than boosters. Breakthrough infections generated similar antibody levels to boosters, and the subsequent antibody declines were slightly slower than after boosters. Together our findings show breakthrough infection provides longer-lasting protection against further infections than booster vaccinations. Our findings, considered alongside the risks of severe infection and long-term consequences of infection, have important implications for vaccine policy.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-38275-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-38275-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-38275-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().